At a glance
ClinicalIndex Comparison RecordN/ACompleted· 14 enrolled
Drug / intervention
3D MR Fingerprinting scandevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Assessment of Response to Neo-Adjuvant Chemotherapy in Breast Cancer
In Brief
A clinical study evaluating 3D MR Fingerprinting scan for Breast Cancer. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if new methods of MRI imaging can better measure participants' response to chemotherapy treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartJan 2019
Primary CompletionApr 2023
TodayJul 2026
First PostedAug 29, 2018
Enrollment StartJan 14, 2019
Primary CompletionApr 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.8 years ago
Interventions
3D MR Fingerprinting scandevice
3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast. MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan.